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angiotensin-converting enzyme levels. At the time of admit-
tance with signs of cardiac shock, his cardiac output was eval-
uated to be 1.5l with an ejection fraction of 12%. We implant-
ed a pneumatically driven BIVAD (Thoratec) and the patient
was bridged to transplantation for 90 days (Fig 1). His inten-
sive course was complicated by an initial general blood-borne
septic event with cultured Staphylococcus aureus and
Candida albicans. This was treated by broad-spectrum antibi-
otics/mycotics (vancomycin, cefuroxime, and fluconazole).
Moreover, on day 50 the patient had a spleen infarction veri-
fied by computed tomography. No therapeutic consequence
was drawn. Anticoagulation was initially maintained with
heparin and was switched after 10 days to phenprocoumon
(Marcoumar). The patient recovered well and was transferred
to the normal ward on day 86. After 90 days of mechanical
assisted support, an appropriate donor heart became available
and bicaval heart transplantation was performed. The recipi-
ent’s heart was histologically evaluated and characteristic sar-
coidosis granulomas were documented (Fig 2). After heart
Sarcoidosis of the heart is an unusual but previously report-
ed indication for transplantation. Sarcoidosis is a systemic
disease that can manifest itself with arrhythmias and car-
diomyopathy. The case presented here is that of a 30-year-old
man in whom an implantable cardioverter and a biventricular
assist device (BIVAD) were used to bridge the time to heart
allograft transplantation.
Noncaseating granulomas were first autopsy proven in
1929, indicating heart involvement in sarcoidosis.1 In 1935
Salvesen2 described a patient with known sarcoidosis and
bundle branch block on electrocardiogram that was believed
to be clinically consistent with the diagnosis of cardiac sar-
coidosis. Since that time, a large number of reviews has
shown that the combination of arrhythmias and sudden death,
seen in about 50% to 60% of patients with cardiac sarcoido-
sis, constitutes the most prevalent and lethal complication of
the disease.3 This led to the prophylactic implantation of
implantable cardioverter-defibrillators in this patient popula-
tion with documented success in bridging to transplantation.4
We are reporting in this article the first successful implanta-
tion and bridging to transplantation with a BIVAD (Thoratec
Corporation, Pleasanton, California) in a patient with med-
ically intractable cardiac failure.
Clinical summary. A 30-year-old man with lung biop-
sy–proven sarcoidosis was admitted to our intensive care unit
in cardiac shock. The disease was diagnosed when he was 17
years old, when he had symptoms of dyspnea, fatigue, weight
loss, and fever. Signs of Loefgren’s syndrome were absent. A
diagnostic thoracotomy and lung biopsy with detection of
characteristic granulomas confirmed the diagnosis of sar-
coidosis. After treatment with steroids, he recovered and
remained in stable condition with low-dose immunosuppres-
sion. Ten years after this first manifestation, chest pain and
palpations were reported, and he was monitored with a Holter
electrocardiogram and echocardiography. The echocardio-
gram revealed an enlarged 4-chamber view and the electro-
cardiogram documented Lowen grade IV arrhythmia. This led
to the prophylactic implantation of an implantable cardiover-
ter-defibrillator, modification of the immunosuppression, and
initiation of cardiomyopathy treatment (angiotensin-convert-
ing enzyme inhibitors and digitalis) with normalization of
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Fig 1. Transthoracic x-ray film showing enlarged heart with
biventricular Thoratec inflow and outflow conduits and auto-
mated cardiac defibrillator.
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transplantation, induction therapy was initiated with antithy-
mocyte globulin (2 mg/kg) for 5 days and triple therapy with
steroids, azathioprine, and cyclosporine (INN: ciclosporin).
However, the patient had International Society for Heart and
Lung Transplantation grade II/III rejection rates in 2 consec-
utive weeks after allograft transplantation, which were steroid
resistant. Therapy was switched to mycophenolate and high
doses of FK506. With this therapy regimen, endomyocardial
biopsy tissue normalized and the patient was discharged after
3 weeks. His postoperative course has since been uneventful.
Discussion. Sarcoidosis is a systemic disease and the clin-
ical manifestation may be generalized or focused on one or
more organs. Because the lung is almost always involved,
however, most patients have symptoms referable to the respi-
ratory system. Independent of the site, the clinical manifesta-
tions relate directly to inflammation and organ dysfunction
caused by the granulomatous disease process. The frequency
of clinical heart involvement in patients with systemic sar-
coidosis is extremely low and in one series was reported to be
less than 2%.5 Most of the patients with cardiac sarcoidosis
who have clinical manifestations present with conduction dis-
turbances or arrhythmias or, less commonly, with pump fail-
ure. Those with primary heart involvement do, however, have
a high incidence of sudden cardiac death.6 There have been
case reports of patients with cardiac sarcoid undergoing heart
transplantation, and sarcoidosis was advocated to be a relative
indication for allograft transplantation.7 Reports have docu-
mented recurrence of sarcoidosis in a cardiac allograft after
transplantation.8 One article even showed that transmission of
sarcoidosis via cardiac transplantation was possible.9 These
observations supported the observation by Mitchell and
Rees10 that the disease was transmissible with human sarcoid
tissue, thus being an infectious agent.
At the time of this report and in contrast to the literature,
bridging to transplantation with a BIVAD had not been
reported with regard to this disease. There are several aspects
of this case that deserve comment. First, to our knowledge,
this is the first report that bridging with a BIVAD is possible
in this type of patient. Second, in this case, postimplantation
severe sepsis was present, indicating BIVAD-induced suscep-
tibility to blood-borne germs and decreased immune compe-
tence.11 Third, despite aggressive anticoagulation (interna-
tional normalized ratio 2.5-3.5), a spleen infarction with
hyperthermia developed. Finally, at least in this patient, there
was a clear hyperimmune response as indicated by steroid-
resistant rejection episodes, thus indicating that aggressive
immune suppression should be initiated after support with a
cardiac assist device. 
It has not yet been determined that this particular systemic
disease can be controlled long term with appropriate
immunosuppression. Thus, we contend that this patient was
saved by implanting a BIVAD to bridge to transplantation for
sarcoidosis, hence indicating a new experimental therapy.
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Fig 2. After being sampled, the heart was formaldehyde
fixed, paraffin embedded, and histologically evaluated. All
blocks presented interstitial edema, mild-to-moderate peri-
vascular lymphohistocytic infiltrate, and small numbers of
noncaseating granulomas composed of aggregated epithe-
lioid cells containing Langerhans-type multinucleated giant
cells including an asteroid body within the cytoplasm as
shown in the photomicrograph (hematoxylin and eosin; orig-
inal magnification ×400).
